Financial Performance - In the first quarter of 2024, the company achieved a total revenue of RMB 165.82 million, a decrease of 12.44% year-on-year[8] - Sales revenue from the core product, Oubatinib (Yinokai®), reached RMB 164.80 million, representing a year-on-year growth of 8.87%[8] - The gross profit margin for the first quarter of 2024 was 85.4%, an increase of 8.1 percentage points compared to 77.3% in the same period last year[7] - The company reported a net loss attributable to shareholders of RMB 142.40 million for the first quarter[8] - Total revenue for Q1 2024 was ¥165,824,020.34, a decrease of 12.43% compared to ¥189,387,628.40 in Q1 2023[20] - Net loss for Q1 2024 was ¥145,660,375.68, compared to a net loss of ¥14,229,365.40 in Q1 2023, indicating a substantial decline in profitability[20][21] - The company's basic earnings per share for Q1 2024 was -¥0.08, compared to -¥0.01 in Q1 2023, highlighting a deterioration in earnings performance[21] Research and Development - Research and development expenses totaled RMB 177.73 million, accounting for 107.18% of total revenue, an increase of 32.75 percentage points year-on-year[8] - Research and development expenses rose to ¥177,728,720.87, an increase of 26.06% from ¥140,950,687.03 in Q1 2023, reflecting a focus on innovation[20] Cash Flow and Liquidity - The company experienced a net cash outflow from operating activities of RMB 84.04 million in the first quarter[8] - Cash flow from operating activities showed a net outflow of ¥84,043,543.78, improving from a larger outflow of ¥154,802,409.78 in Q1 2023[23] - Cash and cash equivalents at the end of Q1 2024 totaled ¥4,616,481,748.24, up from ¥3,993,788,388.71 at the end of Q1 2023, indicating improved liquidity[23] - The company reported a significant increase in cash inflow from investment activities, totaling ¥502,674,850.75, compared to a net outflow of ¥1,915,385.25 in Q1 2023[23] - As of March 31, 2024, the company held cash and cash equivalents of approximately RMB 8.2 billion[7] - The company's cash and cash equivalents as of March 31, 2024, amount to ¥8,201,839,334.55, a decrease from ¥8,287,136,644.81 as of December 31, 2023[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 17,655[12] - The total number of issued shares is 1,762,582,452, with 1,497,934,235 shares (approximately 84.99%) issued in Hong Kong and 264,648,217 shares (approximately 15.01%) issued on the Shanghai Stock Exchange[12] - The top shareholder, HKSCC NOMINEES LIMITED, holds 730,634,157 shares, representing 41.44% of the total shares[14] - The second-largest shareholder, HHLR Fund, L.P. and its concerted actors, holds 208,671,222 shares, accounting for 11.84%[14] - The company has not disclosed any significant changes in shareholder relationships or concerted actions among the top shareholders[15] Assets and Liabilities - The total assets decreased to ¥9,766,283,263.59 from ¥9,919,995,852.46 in the previous quarter, reflecting a reduction in overall company size[19] - The total liabilities decreased slightly to ¥2,712,214,039.61 from ¥2,739,290,198.68, indicating a minor improvement in the company's debt position[19] - Accounts receivable decreased to ¥232,958,854.23 from ¥276,377,549.08 over the same period[18] - Total current assets decreased to ¥8,620,713,615.47 from ¥8,765,324,062.77[18] - Non-current assets totaled ¥1,145,569,648.12, down from ¥1,154,671,789.69[18] - The company reported a decrease in long-term equity investments from ¥5,660,187.95 to ¥4,320,662.46[18] Accounting and Reporting - The company has adopted new accounting standards starting from 2024, impacting the financial statements from the beginning of the year[24] - The financial report is presented by Jisong Cui, the head of the company, along with key accounting personnel[24] - The report indicates that the company is not applicable for the new accounting standards or interpretations[24] - The announcement was made by the board of directors of the company on May 13, 2024[24] - The document contains a total of 14 pages, indicating a comprehensive report[24] - The company is focused on ensuring the accuracy of financial reporting under the new standards[24] - There are no specific performance metrics or user data provided in this document[24] - Future outlook and performance guidance are not detailed in this report[24] - No information on new products, technologies, market expansion, or mergers and acquisitions is included[24] - The report does not provide any financial figures or percentage changes[24] Product Information - Oubatinib is the first and only BTK inhibitor approved for the MZL indication in China, listed as a Class I recommendation in the CSCO lymphoma treatment guidelines[7]
诺诚健华(09969) - 2024 Q1 - 季度业绩